Targin 20mg/10mg prolonged release tablets
*Company:
Mundipharma Pharmaceuticals Limited - Formerly Napp LaboratoriesStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company

Updated on 28 February 2025
File name
Proposed_IE_PIL_Targin_Prolonged Release Tablets_5_2.5 mg, 10_5 mg, 20_10 mg, 40_20 mg_clean.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 4 - possible side effects
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
2. What you need to know before you take Targin
Contact your doctor if you experience severe upper abdominal pain possibly radiating to the back, nausea, vomiting or fever as this could be symptoms associated with inflammation of the pancreas (pancreatitis) or the biliary tract system.
Other medicines and Targin
· muscle relaxants;
· medicines to treat Parkinson’s disease.
4. Possible side effects
Not known (frequency cannot be estimated from the available data)
- a problem affecting a valve in the intestines that may cause severe upper abdominal pain (sphincter of Oddi dysfunction)
6. Contents of the pack and other information
What Targin looks like and contents of the pack
These tablets are available in blister packs of 10, 14, 20, 28, 30, 50, 56, 60, 98 and 100 or in a hospital pack of 100 (10 x 10) or in a bottle with child-resistant closure containing 100 tablets.
This leaflet was last revised in July 2024.
Updated on 28 February 2025
File name
ie-spc-targin-20 mg-10 mg-clean.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each prolonged‑release tablet contains 5 mg of oxycodone hydrochloride equivalent to 4.5 mg oxycodone and 2.5 mg naloxone hydrochloride as 2.73 mg of naloxone hydrochloride dihydrate equivalent to 2.25 mg naloxone.
Excipient with known effect: Each prolonged‑release tablet contains 71.8 mg lactose monohydrate
For the full list of excipients, see section 6.1.
4. CLINICAL PARTICULARS
Below point has been added in Section 4.4
4.4 Special warnings and precautions for use
Hepatobiliary disorders
Oxycodone may cause dysfunction and spasm of the sphincter of Oddi, thus increasing the risk of biliary tract symptoms and pancreatitis. Therefore, oxycodone / naloxone has to be administered with caution in patients with pancreatitis and diseases of the biliary tract.
Below point has been added in Section 4.5
4.5 Interaction with other medicinal products and other forms of interaction
Concomitant administration of oxycodone with anticholinergics or medications with anticholinergic activity (e.g. tri-cyclic antidepressants, antihistamines, anti-psychotics, muscle relaxants, anti-Parkinson drugs) may result in increased anticholinergic adverse effects.
10. DATE OF REVISION OF THE TEXT
Updated on 09 May 2024
File name
PIL Targin Prolonged Release Tablets 5-2.5-10-5-20-10-40-20mg - clean - Sept 23.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 5 - how to store or dispose
- Change to section 6 - date of revision
- Change to other sources of information section
Updated on 09 May 2024
File name
Targin Prolonged Release Tablets-20-10mg-clean - Sept 23.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 07 June 2023
File name
Patient Leaflet-PIL English Targin Prolonged Release Tablets 5-2.5-10-5-20-10-40-20mg - clean.pdf
Reasons for updating
- Change to section 6 - what the product looks like and pack contents
Updated on 07 June 2023
File name
Targin Prolonged Release Tablets-SmPC-20-10mg-clean.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 06 April 2023
File name
Targin Prolonged Release Tablets-20-10mg-clean.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
IE MAH Address Change
Updated on 06 April 2023
File name
Patient Leaflet-PIL English Targin Prolonged Release Tablets 5-2.5-10-5-20-10-40-20mg - clean.pdf
Reasons for updating
- New PIL for new product
Free text change information supplied by the pharmaceutical company
IE MAH Address Change
Mundipharma Pharmaceuticals Limited - Formerly Napp Laboratories

Address:
United Drug House Magna Drive, Magna Business Park, Citywest Road, Dublin 24, IrelandMedical Information E-mail:
medicalinformation@mundipharma.ieTelephone:
Medical Information Direct Line:
+44 174 882 8867